Three things to know:
1. The biotechnology company is the third to receive approval for an SMA drug. Biogen’s Spinraza and Novartis’ Zolgensma have also been commercialized.
2. In two clinical trials, Evrysdi has shown improvement in people of varying ages and severity of SMA. The liquid drug is administered daily by mouth or feeding tube.
3. Evrysdi’s market price is set at $340,000 annually and is based on the weight of the patient. Some younger patients could receive the drug for less than $100,000 a year.
More articles on biologics:
Acquisitions, leadership changes & more: 6 big moves from Medtronic
Zimmer Biomet’s worldwide knee sales plummet 46.8% in Q2, hitting $374M
9 spine surgeons stepping into new leadership roles
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 18–20 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
